Vericel Corporation

Valuation Analysis

About the Company

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burn

Vericel Corporation Stock at a Glance

Vericel Corporation (VCEL) is currently trading at $37.46 with a market capitalization of $1.9B. The trailing P/E ratio stands at 87.12x, with a forward P/E of 43.97x. The 52-week range spans from $28.95 to $43.57; the current price is 14% below the yearly high. Year-over-year revenue growth stands at +30.1%. The net profit margin stands at 7.35%.

💰 Dividend

Vericel Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

7 analysts rate Vericel Corporation (VCEL) on consensus: Strong Buy. The average price target is $55.43, implying +47.97% from the current price. Analyst price targets range from $42.00 to $70.00.

Vericel Corporation: The Investment Case in Detail

Vericel Corporation (VCEL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 30.1% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 74.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 47.97% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Short interest sits at 12.81% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 66.77x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 43.97x is meaningfully below the trailing 87.12x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 47.97% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (12.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Vericel Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.